Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Devon Conway

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 21, 2018
Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60Le H Hua, Tracey H Fan, Devon Conway, et al.
Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association|June 18, 2010
National Institutes of Health stroke scale assists in predicting the need for percutaneous endoscopic gastrostomy tube placement in acute ischemic strokeAmer Alshekhlee, Nishant Ranawat, Tanvir U Syed, et al.
International Journal of MS Care|April 21, 2021
Impact of Switching to Fingolimod Versus Injectable Disease-Modifying Therapy Cycling on Risk of Multiple Sclerosis-Related Relapses: A Retrospective AnalysisMaria Cecilia Vieira, Yunfeng Li, Xiangyi Meng, et al.
Current Medical Research and Opinion|November 8, 2019
Time to treatment failure following initiation of fingolimod versus teriflunomide for multiple sclerosis: a retrospective US claims studyMaria Cecilia Vieira, Devon Conway, Gina Mavrikis Cox, et al.
Neurodegenerative Disease Management|January 30, 2026
Real-world experience of ozanimod in adults with multiple sclerosisJessica Cooperrider, Jeffrey Lambe, Michelle Chu, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 6, 2021
Interpreting change on the Symbol Digit Modalities Test in people with relapsing multiple sclerosis using the reliable change methodologyZachary Weinstock, Sarah Morrow, Devon Conway, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 1, 2020
Quantifying cognition and fatigue to enhance the sensitivity of the EDSS during relapsesSarah A Morrow, Devon Conway, Tom Fuchs, et al.
Advances in Therapy|April 30, 2026
Comparative Effectiveness of Diroximel Fumarate vs. Dimethyl Fumarate in Persons with Multiple Sclerosis: A US Claims Analysis of Relapse OutcomesDaniel Bandari, Devon Conway, Liang Dong, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 30, 2023
Detecting isolated cognitive relapses in persons with MSSarah A Morrow, Zachary L Weinstock, Omid Mirmosayyeb, et al.
Neurological Research and Practice|July 31, 2024
Multidisciplinary lifestyle interventions for neurological disorders during the Silent phase (MINDS) study: a multi-omics randomized controlled trial protocolSara Taylor, Seerat Sachdeva, Sandra Darling, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 21, 2018
Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60Le H Hua, Tracey H Fan, Devon Conway, et al.
Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association|June 18, 2010
National Institutes of Health stroke scale assists in predicting the need for percutaneous endoscopic gastrostomy tube placement in acute ischemic strokeAmer Alshekhlee, Nishant Ranawat, Tanvir U Syed, et al.
International Journal of MS Care|April 21, 2021
Impact of Switching to Fingolimod Versus Injectable Disease-Modifying Therapy Cycling on Risk of Multiple Sclerosis-Related Relapses: A Retrospective AnalysisMaria Cecilia Vieira, Yunfeng Li, Xiangyi Meng, et al.
Current Medical Research and Opinion|November 8, 2019
Time to treatment failure following initiation of fingolimod versus teriflunomide for multiple sclerosis: a retrospective US claims studyMaria Cecilia Vieira, Devon Conway, Gina Mavrikis Cox, et al.
Neurodegenerative Disease Management|January 30, 2026
Real-world experience of ozanimod in adults with multiple sclerosisJessica Cooperrider, Jeffrey Lambe, Michelle Chu, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 6, 2021
Interpreting change on the Symbol Digit Modalities Test in people with relapsing multiple sclerosis using the reliable change methodologyZachary Weinstock, Sarah Morrow, Devon Conway, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 1, 2020
Quantifying cognition and fatigue to enhance the sensitivity of the EDSS during relapsesSarah A Morrow, Devon Conway, Tom Fuchs, et al.
Advances in Therapy|April 30, 2026
Comparative Effectiveness of Diroximel Fumarate vs. Dimethyl Fumarate in Persons with Multiple Sclerosis: A US Claims Analysis of Relapse OutcomesDaniel Bandari, Devon Conway, Liang Dong, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 30, 2023
Detecting isolated cognitive relapses in persons with MSSarah A Morrow, Zachary L Weinstock, Omid Mirmosayyeb, et al.
Neurological Research and Practice|July 31, 2024
Multidisciplinary lifestyle interventions for neurological disorders during the Silent phase (MINDS) study: a multi-omics randomized controlled trial protocolSara Taylor, Seerat Sachdeva, Sandra Darling, et al.
Pageof 2